Critics of the South African government argue that it has done too little too late to secure vaccines, and that it doesn't have a proper plan in place for rollout.
Academic rigor, journalistic flair
Articles on COVAX
Displaying all articles
Many countries cannot afford to buy existing COVID-19 vaccines, a collective approach is needed.
CC BY-NC-ND16.4 MB (download)
It’s unlikely South Africa will have a substantial number of vaccines until the second half of this year. Most of the vaccines produced in Europe or America have been bought by other countries.
A waiver on some intellectual property rules at the WTO for COVID-19 vaccines would ensure more equitable access, but wouldn't solve all the problems facing developing countries.
Unprecedented efforts are driving the global push for a safe and effective vaccine. If and when we have one (or more), here's how it's likely to be rolled out in Australia.
Side agreements signed by some wealthy nations threaten to undercut global efforts to ensure a fairly equitable worldwide vaccination effort.
The Trump administration wants to go it alone when it comes to vaccine development and distribution. What does this mean for the U.S. and the world?
With $1 billion in advance purchase agreements for COVID-19 vaccines, Canada has joined the vaccine nationalists: rich countries buying up more than half the global short-term supply of vaccine.
Australia's contribution to the global COVAX initiative helps secure future vaccines. Here's the full field of candidates.
More than 170 countries have signed up to the Global Access (COVAX) initiative, but vaccine hoarding has already begun by many wealthy countries — leaving poorer nations potentially in the lurch.
Top contributors
-
Professor and Distinguished Research Chair, Globalization and Health Equity, L’Université d’Ottawa/University of Ottawa
-
Professor of Philosophy, Binghamton University, State University of New York
-
Professor of Vaccinology and Director of the SAMRC Vaccines and Infectious Diseases Analytical Research Unit, University of the Witwatersrand
-
Professor in Infectious Diseases Epidemiology, Monash University
-
Associate professor, University of Sydney
-
Paediatrician, Infectious Diseases Physician and Clinical Microbiologist, University of Western Australia
-
Part-time lecturer at the Global Health & Social Medicine, Harvard Medical School and lecturer at the School of Public Health, College of Health Sciences, University of Liberia
-
Early Career Research Leader, Emerging Viruses, Inflammation and Therapeutics Group, Menzies Health Institute Queensland, Griffith University
-
Professeure titulaire, École de santé publique, Université de Montréal
-
Assistant Professor, School of Nursing, Faculty of Health & Social Development, University of British Columbia
-
Clinical associate professor, Faculty of Medicine, University of British Columbia
-
Professor of Law, Northeastern University
